United States, White House team, Boosters start Septemberhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscasesUploaded 18-08-21https://covid.cdc.gov/covid-data-tracker/#vaccination-trendshttps://covid.cdc.gov/covid-data-tracker/#hospitalizations(FDA depending)Eight months after Pfizer or Moderna Same brandNews on second dose of J and J in the next few weeksMr. Greg Abbott in TexasTested positive for COVID-19 on TuesdayIs in good health and experiencing no symptomsMr. Abbott was vaccinated in DecemberAll close contacts being notifiedMay not always have been wearing a mask recentlySeven million who are immunocompromisedBooster roll out started in Detroit yesterdayChildrenCases, + 121,427 in past 7 daysHospital admissions, x 3 in past 7 daysPredictive indicators seem to have changedData from Israel Health Ministryhttps://www.medrxiv.org/content/10.1101/2021.07.29.21261317v1.full.pdfN = 2.5 million (16 and over)Second dose administered within the 21 to 28 day interval set by national guidelines A significant drop in protection against hospitalization among people age 65 and olderWho were vaccinated in January and FebruaryDelta (B.1.617.2) variant became the dominant strain in Israel in June 2021Israel is currently experiencing a new surge of casesThe correlation between antibody dynamics and clinical protection remains undefined Correlation between time-from-vaccine and incidence of breakthrough infectionWe found that the risk for infection was significantly higher for early vaccinees compared to those vaccinated laterModel 1We matched 329,177 persons in each group1,911 cases of breakthrough infection were recorded1,151 of them in the Early Vaccinees group760 in the Late Vaccinees groupWe found a statistically significant 53% increased risk for breakthrough infection in early vaccines (P less than 0.001)We found a similar trend across all age groupsModel 2Individuals who were vaccinated in January 2021Had a 2.26-fold increased risk for breakthrough infectionCompared to individuals who were vaccinated in April 2021Israel has already started beginning giving booster shots to people older than 50.Data on all symptomatic sequenced cases of Covid-19 in EnglandEffectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Varianthttps://www.nejm.org/doi/full/10.1056/NEJMoa2108891After one dose of Pfizer or AZ, delta efficacy = 31%After one dose of Pfizer or AZ, alpha efficacy = 49%After two dose of Pfizer, alpha efficacy = 94%After two dose of Pfizer, delta efficacy = 88%After two dose of AZ, alpha efficacy = 75%After two dose of AZ, delta efficacy = 67%Data from QatarBNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatarhttps://www.medrxiv.org/content/10.1101/2021.08.11.21261885v1Effectiveness against any severe, critical, or fatal COVID-19 disease due to delta was 89.7%Both BNT162b2 (Pfizer) and mRNA-1273 (Moderna) are highly effective in preventing Delta hospitalization and death, but less so in preventing infection(Moderna may protect against symptomatic infection more than Pfizer)Paul A. Offit, pediatrician and vaccine expert at Children’s Hospital of Philadelphiahttps://www.washingtonpost.com/health/breakthrough-infections-covid-vaccine/2021/08/17/44ebcaaa-fea0-11eb-85f2-b871803f65e4_story.htmlWe could have done a much better job at setting realistic expectations for this vaccineAnd I think that’s hurt us. Because I think people get disappointed. They think the vaccine isn’t working.”Centers for Disease Control and Prevention (Leaked PP)https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_w https://edition.cnn.com/2021/07/30/health/breakthrough-infection-masks-cdc-provincetown-study/index.htmlJuly 29, 35,000 breakthrough infect
Learn more about your ad choices. Visit megaphone.fm/adchoices